MedTrace Logo

Losartan and Social Processing

NCT06624904 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-07-28

No results posted yet for this study

Summary

This study explores the effects of single-dose losartan (50mg) versus placebo on social processing in healthy volunteers.

Conditions

  • Social Cognition

Interventions

DRUG

Losartan potassium 50mg

Single dose losartan (50 mg), encapsulated identically to placebo.

OTHER

Placebo

Single tablet encapsulated identically to placebo.

Sponsors & Collaborators

  • Oxford Health Biomedical Research Centre (OH BRC) support scheme

    collaborator UNKNOWN

  • University of Oxford

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-19
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06624904 on ClinicalTrials.gov